GLP-1 injections on TikTok: what first-dose videos leave out

What did @britgetsfitandfab actually say?

Britney documented her first self-injection of compounded tirzepatide through a telehealth service called WeightCare, walking viewers through prep steps while skipping the injection itself on camera. She's doing this because her insurance stopped covering weight loss medication, and she's framing it as a cost-saving option for others in the same situation.

To her credit, she stuck closely to the instructional guide provided by the compounding pharmacy. She mentioned washing hands, wiping the injection site and vial top with alcohol, pinching the skin at the abdomen, and drawing "13 units" for her first four-week dose. She did not claim the medication would cure anything, did not exaggerate outcomes, and was upfront that she was nervous and working from written instructions. That's actually a more responsible framing than most GLP-1 content on TikTok.

What she did not address, probably because she doesn't know, is the meaningful distinction between compounded tirzepatide and the FDA-approved branded version. That gap matters more than most creators realize.

Does the science back this up?

The clinical evidence for tirzepatide as a weight management drug is genuinely strong. The core concern here is not the drug itself but the compounded version of it.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at the highest dose produced a mean body weight reduction of about 20.9% over 72 weeks in adults with obesity. That's a real and significant effect. The SURMOUNT-2 trial extended similar findings to people with obesity and type 2 diabetes. So if someone is prescribed tirzepatide by a licensed provider and takes it correctly, the pharmacology is well-supported.

Compounded versions are a different question. The FDA has repeatedly warned that compounded drugs, including those containing tirzepatide, are not FDA-approved and have not been evaluated for safety or efficacy. In late 2024, the FDA determined that a shortage of tirzepatide no longer existed, which means most compounding of tirzepatide is no longer legally permitted under federal shortage exemptions. There have also been reports of adverse events linked to compounded GLP-1 products, partly due to variable concentrations and the use of salt forms (like tirzepatide base versus the approved peptide form). This is not a minor regulatory footnote. It's a meaningful safety and quality consideration.

What did they get wrong (or right)?

She got the injection prep protocol right. Washing hands, cleaning the vial top and injection site with an alcohol wipe, choosing the abdomen and pinching skin for subcutaneous access, these are all consistent with standard self-injection guidance. She also read from an official guide rather than improvising, which is the correct approach for a first injection.

What she got wrong, or more precisely what she omitted, is any acknowledgment that compounded tirzepatide is not the same as Zepbound or Mounjaro. She describes it simply as "a compounded GLP-1" without noting that the product's potency, sterility, and peptide form are not federally verified. That framing, combined with a referral link and the phrase "I'm trying to save you some money too girl," functions as an implicit product endorsement of a substance with real regulatory and safety questions around it.

She also mentions dosing in units rather than milligrams, which is consistent with how many compounding pharmacies package tirzepatide (in vials requiring syringe measurement), but unit-based dosing introduces more room for user error than a fixed auto-injector pen. She doesn't flag that risk.

What should you actually know?

If you are considering a compounded GLP-1 because insurance won't cover the branded version, the financial pressure is real and legitimate. But there are things worth knowing before you follow a TikTok referral link.

• Compounded tirzepatide is not FDA-approved. As of 2024-2025, the FDA has moved to restrict compounding of tirzepatide because the shortage designation that allowed it has been lifted. Obtaining compounded tirzepatide now may put both patient and provider in legally and clinically uncertain territory.
• Unit-based syringe dosing requires accurate technique. A miscalibrated draw can mean a significant overdose or underdose. Auto-injector pens used for brand-name products remove this variable.
• Side effects of tirzepatide, including nausea, vomiting, gastroparesis-like symptoms, and rare but serious pancreatitis, apply to the drug class regardless of whether it's compounded or branded. Starting a GLP-1 without medical supervision for follow-up is not advisable.
• "My insurance doesn't cover it" is a real problem, but the solution isn't automatically a compounded product from a telehealth app. Patient assistance programs exist for Zepbound and Mounjaro, and eligibility criteria have expanded.

Britney's video is well-intentioned and more careful than average. But good intentions don't resolve the regulatory status of the product she's using, and her audience deserves to know that distinction exists.